GWP
VKTX icon

Gen-Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

Gen-Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Buy
29
+22
+314% +$711 ﹤0.01% 659
2026
Q1 		$228 Hold
7
– – ﹤0.01% 711
2025
Q4 		$246 Hold
7
– – ﹤0.01% 676
2025
Q3 		$184 Hold
7
– – ﹤0.01% 675
2025
Q2 		$186 Hold
7
– – ﹤0.01% 632
2025
Q1 		$169 Hold
7
– – ﹤0.01% 609
2024
Q4 		$282 Buy
+7
New +$399 ﹤0.01% 635

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Gen-Wealth Partners's VKTX Position: Q2 2026 in Review

Gen-Wealth Partners increased its Viking Therapeutics (VKTX) stake by 314% in Q2 2026, buying an estimated $711 and bringing the position to 29 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

Gen-Wealth Partners first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Gen-Wealth Partners held 29 shares of Viking Therapeutics worth $1.13K as of Q2 2026.
  • Gen-Wealth Partners bought 22 Viking Therapeutics shares in Q2 2026, an estimated $711.
  • Viking Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #659 holding.
  • Gen-Wealth Partners first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.